Systemic pain relief after omalizumab injection in patient with hypermobile Ehlers–Danlos syndrome: A case report

Abstract

Key Clinical MessageOmalizumab may be a beneficial adjunct treatment option for hEDS patients require to improve pain control, ability to perform ADLs and functionality and social engagement, and most importantly, quality of life.